Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
Stoter
G
G
Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, The Netherlands.
Goey
S H
SH
Batchelor
D
D
Eggermont
A M
AM
Lamers
C
C
Gratama
J W
JW
Bolhuis
R L
RL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008875:Middle Aged
D016898:Interferon-alpha; D007376:Interleukin-2